|
|
News Breaks | | | | June 21, 2012 | | 13:29 EDT |  | TEVA, LLY | Teva launches generic Symbyax in the United States
Teva Pharmaceutical (TEVA) announced the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the company's generic equivalent of Symbyax. Symbyax is marketed by Lilly (LLY) and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of approximately $82M in the United States, based on IMS sales data. | |
|
News For TEVA;LLY From The Last 14 Days Check below for free stories on TEVA;LLY the last two weeks. |
|
|
| May 22, 2013 | | 16:23 EDT | | TEVA | Alexza Pharmaceuticals chief commercial officer to leave company
 Subscribe for More Information | | | May 21, 2013 | | 07:24 EDT |  | LLY | Global Health Care to host a conference
Subscribe for More Information | | | May 20, 2013 | | 11:27 EDT | | TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information | | | May 16, 2013 | | 08:55 EDT | | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information | | | May 14, 2013 | | 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information | | | 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | May 13, 2013 | | 09:44 EDT |  | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information | | | 07:49 EDT |  | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. | |
|
|
|
|
|
|
